

**Drug Utilization Review (DUR) Meeting Minutes  
June 5, 2019**

**Members Present:** Michael Quast, Gabriela Balf, Tanya Schmidt, Andrea Honeyman, Peter Woodrow, Jesse Rue, LeNeika Roehrich, Kayli Bardell, Michael Quast, Jeffrey Hostetter

**Members Absent:** Michael Booth, Russ Sobotta, Laura Schield, Katie Kram

**Medicaid Pharmacy Department:** Brendan Joyce, Alexi Murphy

**Old Business**

Chair L. Roehrich called the meeting to order at 1:07 p.m. Chair L. Roehrich asked for a motion to approve the minutes of the December meeting. T. Schmidt moved that the minutes be approved and G. Balf seconded the motion. Chair L. Roehrich called for a voice vote to approve the minutes. The motion passed with no audible dissent.

**Review Top 15 Therapeutic Categories/Top 25 Drugs**

B. Joyce presented the quarterly review of the top 15 therapeutic classes by total cost of claims, top 25 drugs based on number of claims, and top 25 drugs based on claims cost for the 1<sup>st</sup> quarter of 2019.

**PDL/PA Criteria Updates**

A. Murphy shared with the Board all of changes made to the Preferred Drug List since the most recent version of the Preferred Drug List was posted. Notable changes included removing PA requirements a number of COPD inhalers and adding numerous agents to recently DUR Board approved PA class criteria. When a new version of the PDL is published and posted to the website, all updates/changes made since the last version are called out at the top of the document itself.

**Second Review of Sivextro and Nuzyra**

A motion and second was made at the December meeting to place Sivextro and Nuzyra on prior authorization. The topics were brought up for a second review. J. Hostetter made a motion to amend the prescriber requirements to include following stewardship or per protocol, and J. Rue seconded the motion. Chair L. Roehrich called for a voice vote to approve the amendment, and the motion passed with no audible dissent. Chair L. Roehrich called for a voice vote to approve the amended criteria, and the motion passed with no audible dissent.

**Second Review of Estrogen Agents**

A motion and second was previously made to place estrogen agents on prior authorization. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

**Second Review of Agents for Treatment of Osteoporosis**

A motion and second was made at the December meeting to place agents for the treatment of osteoporosis on prior authorization. The topic was brought up for a second review. P. Woodrow made a motion to amend the criteria to account for FRAX scores to be included and considered, and J. Hostetter seconded the motion. Chair L. Roehrich called for a voice vote to approve the

amendment, and the motion passed with no audible dissent. There was no public comment. Chair L. Roehrich called for a voice vote to approve the amended criteria, and the motion passed with no audible dissent.

### **Second Review of Agents for the Treatment of Hyperkalemia**

A motion and second was made at the December meeting to place agents for the treatment of hyperkalemia on prior authorization. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

### **Second Review of Agents for the Treatment of Parkinson's Disease**

A motion and second was made at the December meeting to place agents for the treatment of Parkinson's disease on prior authorization. The topic was brought up for a second review. There was no public comment. Chair L. Roehrich called for a voice vote and the motion passed with no audible dissent.

### **New Business**

#### **Review of Short Acting Opioids**

A. Murphy presented a review of short-acting opioid agents to the Board. A motion was made by M. Quast to create PA criteria for the use of these agents and manage these medications through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting.

#### **Review of Agents for Treatment of Thrombocytopenia**

A. Murphy presented a review of agents for treatment of thrombocytopenia to the Board. A motion was made by J. Hostetter. Woodrow to create PA criteria for the use of this agent and manage this medication through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting.

#### **Review of Agents for Treatment of Interstitial Cystitis**

A. Murphy presented a review of agents for treatment of interstitial cystitis to the Board. A motion was made by P. Woodrow to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by J. Rue. This topic will be reviewed at the next meeting.

#### **Review of Agents for Treatment of Narcolepsy**

A. Murphy presented a review of agents for treatment of hyperkalemia to the Board. A motion was made by J. Rue to create a new PA criteria class and manage these medications through prior authorization. The motion was seconded by G. Balf. This topic will be reviewed at the next meeting.

### **Report on Utilization of Benzodiazepines and Opioids Concurrently**

To reduce the risk of respiratory depression, a claims processing edit was put in place limiting the concurrent use of these agents to requiring a prior authorization in 2018. T. DeRuiter presented utilization data showing the number of FFS patients receiving an opioid and benzodiazepine concurrently from 2018 to 2019. The data showed that the number of patients receiving an agent from both of these drug classes was reduced by ~50% since this edit was put in place.

**Retrospective Drug Utilization Review (RDUR) Criteria Recommendations**

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, and new warnings. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. J. Hostetter moved to amend the new criteria as stated above and approve it. J. Rue seconded the motion. The motion passed with no audible dissent.

**Adjournment and Upcoming Meeting Date**

Chair L. Roehrich adjourned the meeting at 2:45 pm. The next DUR Board meeting will be held September 4, 2019 at 1:00 pm at the State Capitol building in the Brynhild -Haugland room.